Abstract
In 1974 there was an increasing awareness at the National Cancer Institute of the U.S.A. that important drugs might have been missed by the conventional murine tumor screening system then employed. Differences in biochemistry and cell biology of murine vs. human tumors were increasingly well understood. Among these were growth kinetic properties, membrane transport rates, preferential metabolic pathways, nucleotide pool regulatory mechanisms, and preferential mode of DNA repair.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Corbett TH, Griswold PD Jr, Roberts BJ, Peckham JC, Schabel F: Evaluation of single agents and combinations of chemotherapeutic agents in mouse colon carcinomas. Cancer 1977 (40): 2660–2680
Johnson RK, Houchens DP: The use of human tumor xenografts for selection of new agents against tumors with response to established drugs. In: Muggia F, Rozencweig M (eds) Lung Cancer: Progress in therapeutic research. Raven Press, New York, 1979 pp 37–44
Osieka R, Houchens DP, Goldin A, Johnson RK: Chemotherapy of human colon cancer xenografts in athymic nude mice. Cancer 1977 (40): 2640–2650
Osieka R: Chemotherapy studies with human colon cancer xenografts in nude mice. In: Sigenthaler W, Luethy R (eds) Current Chemotherapy Proceedings of the 10th International Congress of Chemotherapy. Zurich, Switzerland, Sept 18–23 1977 American Society for Microbiology (2): 1149–1151
Osieka R, Johnson RK: Evaluation of clinical agents in phase I clinical trial and earlier stages of development against xenografts of human colon carcinoma. In: Houchens DP, Ovejera AA (eds) The use of athymic (nude) mice in cancer research. Gustav Fischer Verlag, New York, Stuttgart, 1978 pp 217–223
Venditti JM: Preclinical drug development: rationale and methods. Semin Oncol 1981 (8): 349–361
Estey E, Hoth D, Simon R, Marsoni S, Leyland-Jones B, Wittes R: Therapeutic response in phase I trial of antineoplastic agents. Cancer Treat Rep 1986 (70): 1105–1115
Thomas CB, Osieka R, Kohn KW: DNA cross-linking by in vivo treatment with 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea of sensitive and resistant human colon carcinoma xenografts in nude mice. Cancer Res 1978 (39): 2448–2454
Erickson LC, Osieka R, Kohn KW: Differential repair of 1 -(2-chloroethyl)-3-(4-methylcyclohexyl)-1 -nitrosourea-in-duced DNA damage in two human colon tumor cell lines. Cancer Res 1978 (38): 802–808
Bergerat JP, Barlogie B, Drewinko B: Effects of cis-dichlorodiammineplatinum (II) on human colon carcinoma cells in vitro. Cancer Res 1979 (39): 1334–1338
Osieka R: Primary and acquired resistance to antineoplastic chemotherapy. Cancer 1984 (54): 1168–1174
Hill JM, Loeb E, Pardue AS, Khan A, Hill NO, King JJ, Hill RW: Platinum coordination compounds in the treatment of acute leukemia and other malignant disease with particular reference to malonato 1,2-diaminocyclohexane platinum (II). J Clin Hemat and Oncol 1977 (7): 681–699
Seeber S, Osieka R, Schmidt CG, Achterrath W, Crooke ST: In vivo resistance towards anthracyclines, etoposide. Cancer Res 1982 (42): 4719–4725
Osieka R, Glatte P, Pannenbaecker R, Schmidt CG: Therapeutic evaluation of five nitrosoureas in a human melanoma xenograft system. Cancer Chemother Pharmacol 1983(11): 147–152
Osieka R, Glatte P, Pannenbaecker R, Schmidt CG: Enhancement of methyl-CCNU induced cytotoxicity by chorpromazine and caffeine in a human melanoma xenograft. Cancer Treat Rep 1986 (70): 1167–1171
Frei E, Canellos P: Dose: A critical factor in cancer chemotherapy. Am J Med 1980 (69): 585–594
Fodstad Ø, Aass N, Pihl A: Response to chemotherapy of human malignant melanoma xenografts in athymic mice. Int J Cancer 1980 (25): 453–458
Steel GG, Courtenay VD, Peckham MJ: The response to chemotherapy of a variety of human tumour xenografts. Br J Cancer 1983 (47): 1–13
Becher R, Osieka R, Hossfeld DK, Schmidt CG: Cytogenetic studies in human tumour xenografts. In: Bastert GBA et al (eds) Thymusaplastic nude mice and rats in clinical oncology. Gustav Fischer Verlag, Stuttgart, New York, 1981 pp 329–334
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1988 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Osieka, R. (1988). Preclinical Drug Evaluation with Human Melanoma Xenografts. In: Winograd, B., Peckham, M., Pinedo, H.M. (eds) Human Tumour Xenografts in Anticancer Drug Development. ESO Monographs. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-73252-2_7
Download citation
DOI: https://doi.org/10.1007/978-3-642-73252-2_7
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-73254-6
Online ISBN: 978-3-642-73252-2
eBook Packages: Springer Book Archive